LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Lenz Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.736 Good morning, ladies and gentlemen, and welcome to the Lens Therapeutics year-end 2024 00:00:05.736 -- 00:00:10.861 financial results conference call. This time, all participants are 00:00:10.861 -- 00:00:16.186 in a listen-only mode. Following prepared remarks from the management, we will conduct 00:00:16.186 -- 00:00:21.791 a question-and-answer session with instructions we'll follow at that time. 00:00:21.791 -- 00:00:23.913 As a reminder, this call is being recorded. 00:00:23.913 -- 00:00:29.258 At this time, I would like to turn the call over to Dan Chevalard, 00:00:29.258 -- 00:00:33.280 Chief Financial Officer. Please go ahead. 00:00:34.423 -- 00:00:37.927 Thank you. Good afternoon, and thank you for joining us today. 00:00:37.927 -- 00:00:42.271 My name is Dan Chevalard, Chief Financial Officer of Lenz Therapeutics. 00:00:42.271 -- 00:00:46.916 We are joined today by Eif Schimelpennig, our President and Chief Executive Officer, 00:00:46.916 -- 00:00:50.640 and Sean Olson, our Chief Commercial Officer, as well as Dr. 00:00:50.640 -- 00:00:56.748 Mark Odrich, Chief Medical Officer, who will join us for the question and answer session. 00:00:56.748 -- 00:01:00.653 Before we begin, I would like to remind you that this call will contain forward-looking 00:01:00.653 -- 00:01:04.439 statements regarding LENZ's future expectations, 00:01:04.439 -- 00:01:09.446 plans, prospects, corporate strategy, regulatory and commercial 00:01:09.446 -- 00:01:11.528 plans and expectations, 00:01:11.528 -- 00:01:15.013 cash runway projections, and performance. 00:01:15.013 -- 00:01:20.601 Actual results may differ materially from those indicated by these forward-looking statements 00:01:20.601 -- 00:01:23.798 as a result of various important facto...